A hydroxyl-modified cationic iridium complex, its preparation method and application
By introducing long alkyl chains onto the auxiliary ligands of iridium complexes, the intermolecular stacking mode of iridium complexes was regulated, thus solving the problems of aggregation quenching and film formation of iridium complexes and realizing aggregation-induced phosphorescence enhancement and solution-processable solid phosphorescent thin film materials.
Patent Information
- Application Number
- CN202611132611.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-29
- Publication Date
- 2026-11-17
AI Technical Summary
Traditional iridium complexes are prone to intermolecular aggregation at high concentrations or in the solid state, leading to triplet-triplet annihilation and concentration quenching. They also have poor film-forming properties, which limits their application in optoelectronic devices.
By introducing long alkyl chains onto auxiliary ligands, the intermolecular stacking mode of iridium complexes was regulated, and hydroxyl-modified cationic iridium complexes were prepared. The film-forming properties and luminescence properties were improved by using cyclometalation and coordination reaction methods.
This study achieves aggregation-induced phosphorescence enhancement, where the luminescence properties of the iridium complex and the film-forming properties of the alkyl chain complement each other, providing a design concept for green, environmentally friendly, and solution-processable solid phosphorescent thin film materials.
Smart Images

Figure CN123106775A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of organic optoelectronic functional materials technology, specifically to a hydroxyl-modified cationic iridium complex, its preparation method, and its application. Background Technology
[0002] Iridium complexes have attracted considerable attention in organic light-emitting devices, bioimaging, and optical sensing due to their high quantum efficiency, tunable emission color, and long excited-state lifetime. However, traditional iridium complexes are prone to intermolecular aggregation under high concentration or solid-state conditions, leading to triplet-triplet annihilation and concentration quenching, which severely weakens their luminescence efficiency. Furthermore, most iridium complexes exhibit poor film-forming properties, making it difficult to form uniform and stable films, thus limiting their practical application in optoelectronic devices.
[0003] To address the aforementioned issues, researchers have attempted to dope iridium complexes into polymer matrices to isolate luminescent centers and suppress aggregation quenching. However, existing methods for doping polymer matrices suffer from compatibility problems. Furthermore, traditional iridium complexes exhibit poor film-forming properties. This invention aims to improve these properties through molecular design, rather than relying on polymer composites. Additionally, the regulatory mechanism of long alkyl chain modification on the aggregation mode of iridium complexes remains unclear, lacking a systematic approach to controlling the luminescence properties of thin films. Therefore, developing a single, undoped phosphorescent material with excellent film-forming properties, stable luminescence performance, and solution-processability, and establishing a controllable preparation method for it, is of significant research and application value. Summary of the Invention
[0004] The technical problem to be solved by the present invention is to provide a hydroxyl-modified cationic iridium complex and its preparation method. By introducing long alkyl chains on the auxiliary ligand, the intermolecular stacking mode of the iridium complex is controlled to achieve aggregation-induced phosphorescence enhancement properties.
[0005] The technical problem to be solved by this invention is achieved by the following technical solution:
[0006] One objective of this invention is to provide a hydroxyl-modified cationic iridium complex, the structural formula of which is shown below:
[0007]
[0008] Wherein, R is a C9~C14 straight-chain alkyl group.
[0009] The second objective of this invention is to provide a method for preparing the hydroxyl-modified cationic iridium complex, comprising the following steps:
[0010] (1) The main ligand undergoes a cyclometalation reaction with iridium trichloride hydrate to obtain iridium chloride-bridged dimers;
[0011] (2) The chlorinated dimer of iridium undergoes a coordination reaction with the auxiliary ligand to obtain an iridium complex.
[0012] Furthermore, the structural formula of the main ligand is as follows: The structural formula of the auxiliary ligand is as follows: Where R is a C9~C14 straight-chain alkyl group.
[0013] Furthermore, the auxiliary ligand is obtained by reacting 2-(2-pyridyl)benzimidazole with RX; wherein R is a C9~C14 straight-chain alkyl group; and X is a halogen.
[0014] Furthermore, the molar ratio of 2-(2-pyridyl)benzimidazole to RX is 1:(1.1~1.3).
[0015] Furthermore, the molar ratio of the main ligand, the auxiliary ligand, and the iridium trichloride hydrate is (2~3): (1~1.5): 1.
[0016] Furthermore, the reaction temperature of the cyclometalation reaction is 100~130℃, and the reaction time is 10~15 h.
[0017] Furthermore, the ring metallization reaction uses ethylene glycol ethyl ether and deionized water as reaction solvents.
[0018] Furthermore, the coordination reaction is carried out at a temperature of 120-140°C for 10-15 h.
[0019] Furthermore, the coordination reaction uses ethylene glycol ethyl ether as the reaction solvent.
[0020] A third objective of this invention is to provide the application of the hydroxyl-modified cationic iridium complex in phosphorescent materials, aggregation-induced emission materials, solvent polarity responsive materials, aqueous optical sensing materials, and hydrophilic organic optoelectronic functional materials.
[0021] The beneficial effects of this invention are as follows: By introducing 2-(2-pyridyl)benzimidazole modified with a long alkyl chain as an auxiliary ligand, this invention regulates the intermolecular stacking mode of the iridium complex, thereby achieving aggregation-induced phosphorescence enhancement properties; at the same time, by introducing hydroxyl groups onto the main ligand, the water solubility of the iridium complex is improved; and the luminescence performance of the iridium complex and the film-forming properties of the alkyl chain complement each other to compensate for deficiencies, providing a new design idea for developing green, environmentally friendly, solution-processable solid phosphorescent thin film luminescent materials. Attached Figure Description
[0022] Figure 1 The UV-Vis absorption spectra of the iridium complex prepared in Example 1 in methanol / water mixed solvents with different water contents are shown below.
[0023] Figure 2 The UV-Vis absorption spectra of the iridium complex prepared in Example 5 in methanol / water mixed solvents with different water contents are shown below.
[0024] Figure 3 The fluorescence emission spectra of the iridium complex prepared in Example 1 in methanol / water mixed solvents with different water contents are shown.
[0025] Figure 4 The fluorescence emission spectra of the iridium complex prepared in Example 5 in methanol / water mixed solvents with different water contents are shown below.
[0026] Figure 5 The emission spectra of the iridium complex prepared in Example 1 in different solvents;
[0027] Figure 6 The emission spectra of the iridium complex prepared in Example 5 in different solvents are shown.
[0028] Figure 7 This is a scanning electron microscope image of the iridium complex prepared in Example 1 in a methanol / water mixed solvent;
[0029] Figure 8 The image shows a scanning electron microscope (SEM) image of the iridium complex prepared in Example 5 in a methanol / water mixed solvent. Detailed Implementation
[0030] To make the technical means, creative features, objectives and effects of this invention easier to understand, the invention will be further described below with reference to specific embodiments and illustrations.
[0031] Example 1
[0032] (1) Synthesis of the auxiliary ligand (nonyl-2-(2-pyridyl)benzimidazole):
[0033]
[0034] Under nitrogen protection, sodium hydride (0.49 g, 20.48 mmol) was weighed and placed in a dry flask. The flask was cooled in an ice-water bath, and anhydrous tetrahydrofuran (10 mL) was slowly added while stirring. Then, 2-(2-pyridyl)benzimidazole (0.50 g, 2.56 mmol) dissolved in anhydrous tetrahydrofuran (10 mL) was added dropwise. After the addition was complete, the reaction was continued in an ice bath for 2 h. The ice bath was then removed, and the mixture was allowed to warm naturally to room temperature for another 12 h. Subsequently, 1-bromononane (0.64 g, 3.07 mmol) was added, and the mixture was refluxed at 90 °C for 12 h. After the reaction was completed, the reaction solution was cooled to room temperature, and dichloromethane and deionized water were added for extraction. The organic phase was collected, concentrated, and purified by column chromatography (eluent: dichloromethane / n-hexane, v / v) to obtain a colorless viscous product with a yield of 95%. 1 H NMR (400 MHz, MeOD) δ (ppm): 8.80-8.76(m, 1H), 8.25-8.18(m, 1H), 8.07-8.00 (m, 1H), 7.79-7.73 (m, 1H), 7.68-7.61(m, 1H), 7.45-7.37 (m, 2H), 7.27-7.21 (m, 1H), 4.89-4.81 (m, 2H), 1.90-1.84(m, 2H), 1.28-1.22 (m, 12H), 0.93-0.90 (m, 3H).
[0035] (2) Synthesis of iridium chloride-bridged dimers:
[0036]
[0037] Under nitrogen protection, iridium trichloride hydrate (0.52 g, 1.46 mmol) and 4-(2-pyridyl)phenol (0.50 g, 2.92 mmol) were weighed into a dry flask. The flask was cooled in an ice-water bath, and then deionized water (10 mL) and ethylene glycol ethyl ether (40 mL) were slowly added. The mixture was stirred and refluxed at 120 °C for 12 h. After the reaction was completed, the reaction solution was cooled to room temperature, filtered, and dried to obtain a black powder with a yield of 94%.
[0038] (3) Synthesis of iridium complexes with 4-(2-pyridyl)phenol and nonyl group-modified 2-(2-pyridyl)benzimidazole as ligands:
[0039]
[0040] Under nitrogen protection, 0.19 g (0.17 mmol) of iridium chloride-bridged dimer and 0.11 g (0.34 mmol) of 1-nonyl-2-(2-pyridyl)benzimidazole were weighed and placed in a flask. Ethylene glycol ethyl ether (20.00 mL) was added, and the mixture was refluxed at 130 °C for 12 h. After the reaction was completed, the reaction solution was cooled to room temperature and extracted with dichloromethane. The organic phase was collected, concentrated, and purified by column chromatography (eluent: dichloromethane / n-hexane, v / v) to give a dark red product in 64% yield. 1 H NMR(400 MHz, DMSO-d6) δ (ppm): 8.64-8.62 (m, 1H), 8.33-8.29 (m, 2H), 8.04-8.01 (m, 1H), 7.96-7.94 (m, 1H), 7.83-7.71 (m, 4H), 7.63-7.54 (m, 2H), 7.49-7.40 (m, 2H), 7.30-7.18 (m, 2H), 7.11-7.07 (m, 1H), 6.95-6.92 (m, 1H), 6.69-6.63 (m, 1H), 6.54-6.41 (m, 2H), 5.76-5.73 (m, 1H), 5.67-5.62 (m, 1H), 4.98-4.87 (m, 2H), 2.03-1.96 (m, 2H), 1.24 (s, 12H), 0.86-0.81 (m, 3H).
[0041] Example 2
[0042] Synthesis of iridium complexes with 3-(2-pyridyl)phenol and nonyl group-modified 2-(2-pyridyl)benzimidazole as ligands:
[0043]
[0044] The method is the same as in Example 1, except that 4-(2-pyridyl)phenol is replaced with 3-(2-pyridyl)phenol. 1HNMR(400 MHz, DMSO-d6) δ (ppm): 8.64-8.62 (m, 1H), 8.33-8.29 (m, 2H), 8.04-8.01 (m, 1H), 7.96-7.94 (m, 1H), 7.83-7.79 (m, 4H), 7.63-7.54 (m, 2H), 7.49-7.40 (m, 2H), 7.27-7.18 (m, 2H), 7.11-7.07 (m, 1H), 6.95-6.92 (m, 1H),6.82-6.69 (m, 1H), 6.54-6.41 (m, 2H), 5.76-5.73 (m, 1H), 5.67-5.62 (m, 1H), 4.98-4.87 (m, 2H), 2.03-1.96 (m, 2H), 1.24 (s, 12H), 0.86-0.81 (m, 3H).
[0045] Example 3
[0046] Synthesis of iridium complexes with 5-(2-pyridyl)phenol and nonyl group-modified 2-(2-pyridyl)benzimidazole as ligands:
[0047]
[0048] The method is the same as in Example 1, except that 4-(2-pyridyl)phenol is replaced with 5-(2-pyridyl)phenol. 1 HNMR(400 MHz, DMSO-d6) δ (ppm): 8.64-8.62 (m, 1H), 8.33-8.29 (m, 2H), 8.04-8.01 (m, 1H), 7.96-7.94 (m, 1H), 7.83-7.71 (m, 4H), 7.63-7.53 (m, 2H), 7.49-7.40 (m, 2H), 7.27-7.18 (m, 2H), 7.11-7.07 (m, 1H), 6.95-6.92 (m, 1H),6.82-6.69(m, 1H), 6.54-6.41 (m, 2H), 5.76-5.73 (m, 1H), 5.67-5.62 (m, 1H), 4.98-4.87 (m, 2H), 2.03-1.96 (m, 2H), 1.24 (s, 12H), 0.86-0.81 (m, 3H).
[0049] Example 4
[0050] Synthesis of iridium complexes with 6-(2-pyridyl)phenol and nonyl-modified 2-(2-pyridyl)benzimidazole as ligands:
[0051]
[0052] The method is the same as in Example 1, except that 4-(2-pyridyl)phenol is replaced with 6-(2-pyridyl)phenol. 1 HNMR(400 MHz, DMSO-d6) δ (ppm): 8.64-8.62 (m, 1H), 8.33-8.29 (m, 2H), 8.04-8.01 (m, 1H), 7.96-7.94 (m, 1H), 7.83-7.71 (m, 4H), 7.63-7.54 (m, 2H), 7.49-7.40 (m, 2H), 7.32-7.28 (m, 2H), 7.11-7.00 (m, 1H), 6.95-6.92 (m, 1H), 6.69-6.63 (m, 1H), 6.54-6.41 (m, 2H), 5.76-5.73 (m, 1H), 5.67-5.62 (m, 1H), 4.98-4.87 (m, 2H), 2.03-1.96 (m, 2H), 1.24 (s, 12H), 0.86-0.81 (m, 3H).
[0053] Example 5
[0054] (1) Synthesis of the auxiliary ligand (tetradecyl-modified 2-(2-pyridyl)benzimidazole):
[0055]
[0056] The method of Example 1 was followed, except that 1-bromononane was replaced with 1-bromotetradecane, and the eluent for column chromatography purification was dichloromethane / n-hexane at a volume ratio of 1:1, to obtain a colorless viscous product with a yield of 92%. 1H NMR (400MHz, MeOD) δ (ppm): 8.76 (d, J = 4.1 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H), 8.04-7.99 (m, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.54-7.51(m, 1H), 7.42-7.32 (m, 2H), 4.84-4.81 (m, 2H), 1.88-1.81 (m, 2H), 1.30-1.28(m, 22H), 0.93-0.89 (m, 3H).
[0057] (2) Synthesis of iridium chloride-bridged dimers:
[0058] Iridium chloride-bridged dimers were synthesized according to the method in Example 1.
[0059] (3) Synthesis of iridium complexes with 4-(2-pyridyl)phenol and tetradecyl-modified 2-(2-pyridyl)benzimidazole as ligands:
[0060]
[0061] The method is the same as in Example 1, except that the nonyl-modified 2-(2-pyridyl)benzimidazole is replaced with a tetradecyl-modified 2-(2-pyridyl)benzimidazole. 1 H NMR (400 MHz, DMSO-d6) δ (ppm): 8.65-8.63(m, 1H), 8.34-8.27 (m, 2H), 8.12-7.93 (m, 4H), 7.87-7.71 (m, 4H), 7.55-7.40(m, 3H), 7.31-7.06 (m, 3H), 6.94-6.84 (m, 2H), 6.73-6.64 (m, 1H), 6.54-6.43(m, 2H), 4.99-4.88 (m, 2H), 2.04-1.96 (m, 2H), 1.24 (s, 22H), 0.87-0.84 (m,3H).
[0062] Example 6
[0063] Synthesis of iridium complexes with 3-(2-pyridyl)phenol and tetradecyl-modified 2-(2-pyridyl)benzimidazole as ligands:
[0064]
[0065] The method of Example 5 is followed, except that 4-(2-pyridyl)phenol is replaced with 3-(2-pyridyl)phenol. 1 HNMR (400 MHz, DMSO-d6) δ (ppm): 8.65-8.63 (m, 1H), 8.34-8.27 (m, 2H), 8.12-7.93 (m, 4H), 7.87-7.79 (m, 4H), 7.55-7.40 (m, 3H), 7.27-7.06 (m, 3H), 6.94-6.82 (m, 2H), 6.73-6.64 (m, 1H), 6.54-6.43(m, 2H), 4.99-4.88 (m, 2H), 2.04-1.96 (m, 2H), 1.24 (s, 22H), 0.87-0.84 (m, 3H).
[0066] Example 7
[0067] Synthesis of iridium complexes with 5-(2-pyridyl)phenol and tetradecyl-modified 2-(2-pyridyl)benzimidazole as ligands:
[0068]
[0069] The method of Example 5 is followed, except that 4-(2-pyridyl)phenol is replaced with 5-(2-pyridyl)phenol. 1 HNMR (400 MHz, DMSO-d6) δ (ppm): 8.65-8.63 (m, 1H), 8.34-8.27 (m, 2H), 8.12-7.93 (m, 4H), 7.87-7.71 (m, 4H), 7.53-7.40 (m, 3H), 7.27-7.06 (m, 3H), 6.94-6.82 (m, 2H), 6.73-6.64 (m, 1H), 6.54-6.43(m, 2H), 4.99-4.88 (m, 2H), 2.04-1.96 (m, 2H), 1.24 (s, 22H), 0.87-0.84 (m, 3H).
[0070] Example 8
[0071] Synthesis of iridium complexes with 6-(2-pyridyl)phenol and tetradecyl-modified 2-(2-pyridyl)benzimidazole as ligands:
[0072]
[0073] The method of Example 5 is followed, except that 4-(2-pyridyl)phenol is replaced with 6-(2-pyridyl)phenol. 1 HNMR (400 MHz, DMSO-d6) δ (ppm): 8.65-8.63 (m, 1H), 8.34-8.27 (m, 2H), 8.12-7.93 (m, 4H), 7.87-7.71 (m, 4H), 7.55-7.32 (m, 3H), 7.28-7.00(m, 3H), 6.94-6.84 (m, 2H), 6.73-6.64 (m, 1H), 6.54-6.43(m, 2H), 4.99-4.88 (m, 2H), 2.04-1.96 (m, 2H), 1.24 (s, 22H), 0.87-0.84 (m, 3H).
[0074] Example 9
[0075] Photophysical properties testing of iridium complexes (taking the iridium complex prepared in Example 1 as an example):
[0076] (1) Ultraviolet-Visible Absorption Spectroscopy Test: The iridium complex prepared in Example 1 was dissolved in a methanol / water mixed solvent (concentration of 10). -5 In the mixture (M), the volume fractions of water in the mixed solvent were 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90%, respectively. The absorption spectra in the wavelength range of 200–500 nm were measured using a UV-Vis spectrophotometer. Figure 1 As shown.
[0077] from Figure 1 It can be seen that the complex exhibits characteristic absorption peaks at 244 nm, 283 nm, and 320 nm. The strong absorption peaks at 244 nm and 283 nm are attributed to π-π* transitions of the ligands, while the absorption peak at 320 nm is attributed to metal-to-ligand charge transfer (MLCT) transitions. The absorption peak intensity gradually increases with increasing water content in the mixed solvent, and a distinct H-type packing characteristic is observed at high water content, indicating strong intermolecular π-π interactions.
[0078] (2) Aggregation-induced emission performance test: The iridium complex prepared in Example 1 was dissolved in a methanol / water mixed solvent (concentration of 10). -5 M), the volume fractions of water in the mixed solvent are 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, and 90%, respectively. The fluorescence emission spectra are measured using a fluorescence spectrophotometer. Figure 3 As shown.
[0079] from Figure 3 It can be seen that all spectra exhibit phosphorescence emission peaks in the range of 580–620 nm, with the main peak located at approximately 600 nm and a shoulder peak at approximately 622 nm. In pure methanol, the complex exhibits weak luminescence; as the water content increases from 0% to 50%, the luminescence intensity gradually increases, reaching its maximum at 50% water content, with a relative luminescence intensity approximately 2.0–2.2 times that of pure methanol. When the water content exceeds 50%, the luminescence intensity shows a decreasing trend, which is due to the aggregation quenching effect caused by excessive aggregation.
[0080] (3) Solvation effect test: The iridium complex prepared in Example 1 was dissolved in solvents of different polarities, such as n-hexane, toluene, dichloromethane, tetrahydrofuran, methanol, and ethanol, to prepare solutions of the same concentration (concentration of 10). -5 M), and measure its fluorescence emission spectrum, such as Figure 5 As shown.
[0081] from Figure 5 It can be seen that the iridium complex prepared in Example 1 exhibits the weakest luminescence in n-hexane, which is due to the hydrophobicity of the long alkyl chain, resulting in poor solubility in nonpolar solvents; it exhibits the strongest luminescence in methanol and ethanol. With increasing solvent polarity, the emission spectrum generally shows a blue shift trend, indicating that the excited state of this complex possesses certain charge transfer characteristics, and its luminescence performance is significantly modulated by the solvent environment.
[0082] Example 10
[0083] Photophysical properties testing of iridium complexes (taking the iridium complex prepared in Example 5 as an example):
[0084] The method of Example 9 is followed, except that the iridium complex prepared in Example 1 is replaced with the iridium complex prepared in Example 5.
[0085] Figure 2 The UV-Vis absorption spectra of the iridium complex prepared in Example 5 in methanol / water mixed solvents with different water contents. Figure 2 It can be seen that the iridium complex prepared in Example 5 exhibits characteristic absorption peaks at 243 nm, 283 nm, and 320 nm, similar to the iridium complex prepared in Example 1, indicating that the change in alkyl chain length has little effect on the electronic structure of the complex. At high water content, it also exhibits H-type packing characteristics, and due to the longer tetradecyl chain, the hydrophobic interactions between molecules are stronger, resulting in a more pronounced aggregation tendency.
[0086] Figure 4 The fluorescence emission spectra of the iridium complex prepared in Example 5 in methanol / water mixed solvents with different water contents are shown. Figure 4As can be seen, the emission peaks of the iridium complex prepared in Example 5 are located at approximately 598 nm (main peak) and 624 nm (shoulder peak). With increasing water content, the luminescence intensity first increases and then decreases, reaching a peak at 40% water content, with a relative luminescence intensity approximately 1.8 to 2.0 times that of pure methanol. Due to the longer tetradecyl chain and stronger hydrophobicity, aggregation can be triggered at lower water contents; therefore, the peak appears at 40% water content, earlier than that of the iridium complex prepared in Example 1 (50%).
[0087] Figure 6 The emission spectra of the iridium complex prepared in Example 5 in different solvents are shown. Figure 6 It can be seen that the solvation effect of the iridium complex prepared in Example 5 is similar to that of the iridium complex prepared in Example 1: the luminescence is weakest in n-hexane and strongest in methanol and ethanol; the emission spectrum generally blue-shifts with increasing solvent polarity. Because the tetradecyl chain is longer and more hydrophobic, its solubility in nonpolar solvents is worse, thus the luminescence intensity in n-hexane is relatively lower.
[0088] Example 11
[0089] Analysis of the aggregated morphology of iridium complexes (taking the iridium complex prepared in Example 1 as an example):
[0090] The iridium complex prepared in Example 1 was dissolved in methanol, and water was added to prepare an aggregated solution (concentration of 10). -5 M), and uniformly drop-coated onto a silicon wafer, and after drying, its morphology was observed using a scanning electron microscope, such as Figure 7 As shown.
[0091] from Figure 7 As can be seen, the iridium complex prepared in Example 1 formed uniform nanoparticles in the aggregated state, with a uniform particle size distribution and no obvious agglomeration. The formation of nanoparticles helps to reduce direct contact between molecules, thereby inhibiting aggregation quenching, which is one of the important reasons why this complex has aggregation-induced phosphorescence enhancement properties.
[0092] Example 12
[0093] Analysis of the aggregated morphology of iridium complexes (taking the iridium complex prepared in Example 5 as an example):
[0094] The method of Example 11 is followed, except that the iridium complex prepared in Example 1 is replaced with the iridium complex prepared in Example 5.
[0095] Figure 8 The image shows a scanning electron microscope (SEM) image of the iridium complex prepared in Example 5 in a methanol / water mixed solvent. From... Figure 8As can be seen, the iridium complex prepared in Example 5 also formed uniform nanoparticles with a uniform particle size distribution. Due to the longer tetradecyl chain and stronger hydrophobic interaction between molecules, the resulting nanoparticles had a slightly larger particle size than the iridium complex prepared in Example 1, but still maintained good dispersibility and showed no obvious agglomeration.
[0096] In summary, this invention prepares cationic cyclic iridium metal complexes modified with hydroxyl groups at different substitution sites. The introduction of long alkyl chains can regulate the intermolecular stacking mode, achieving aggregation-induced phosphorescence enhancement. In the methanol-water system, the luminescence intensity first increases and then decreases with increasing water content. The nonyl and tetradecyl-modified complexes reach peak values at 50% and 40% water content, respectively, solving the aggregation quenching problem of traditional iridium complexes. The luminescence performance of these complexes is synergistically regulated by the solvent environment and aggregation structure, enabling applications in organic electroluminescent devices, photocatalysis, chemical sensing, and bioimaging.
[0097] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and descriptions in the specification are merely illustrative of the principles of the invention. Various changes and modifications can be made to the invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of the present invention as claimed. The scope of protection of this invention is defined by the appended claims and their equivalents.
Claims
1. A hydroxyl-modified cationic iridium complex, characterized in that, The structural formula of the hydroxyl-modified cationic iridium complex is shown below: ; Wherein, R is a C9~C14 straight-chain alkyl group.
2. The method for preparing the hydroxyl-modified cationic iridium complex according to claim 1, characterized in that, Includes the following steps: (1) The main ligand undergoes a cyclometalation reaction with iridium trichloride hydrate to obtain iridium chloride-bridged dimers; (2) The chlorinated dimer of iridium undergoes a coordination reaction with the auxiliary ligand to obtain an iridium complex; The structural formula of the main ligand is: The structural formula of the auxiliary ligand is as follows: , where R is a C9~C14 straight-chain alkyl group.
3. The preparation method according to claim 2, characterized in that: The auxiliary ligand is obtained by reacting 2-(2-pyridyl)benzimidazole with RX; wherein R is a C9~C14 straight-chain alkyl group; and X is a halogen.
4. The preparation method according to claim 3, characterized in that: The molar ratio of 2-(2-pyridyl)benzimidazole to RX is 1:(1.1~1.3).
5. The preparation method according to claim 2, characterized in that: The molar ratio of the main ligand, auxiliary ligand and iridium trichloride hydrate is (2~3): (1~1.5):
1.
6. The preparation method according to claim 2, characterized in that: The reaction temperature for the cyclometalation reaction is 100~130℃, and the reaction time is 10~15 h.
7. The preparation method according to claim 2, characterized in that: The cyclometalation reaction uses ethylene glycol ethyl ether and deionized water as reaction solvents.
8. The preparation method according to claim 2, characterized in that: The coordination reaction is carried out at a temperature of 120-140℃ for 10-15 h.
9. The preparation method according to claim 2, characterized in that: The coordination reaction uses ethylene glycol ethyl ether as the reaction solvent.
10. The application of the hydroxyl-modified cationic iridium complex of claim 1 in phosphorescent materials, aggregation-induced emission materials, solvent polarity responsive materials, aqueous optical sensing materials, and hydrophilic organic optoelectronic functional materials.
